Research
Hormonal
GLP-1 receptor agonists may increase the risk of thyroid cancer (specifically medullary thyroid cancer) and biliary tract disease, requiring monitoring despite potential cancer benefits.
GLP-1 RAs carry a black box warning for thyroid cancer, particularly medullary thyroid cancer. Patients with a personal or family history of MTC or MEN2 syndrome should not use these drugs. For others, the risk appears low in RCTs but higher in observational studies, so regular monitoring is advised.
ModerateQualifiesMEDIUM confidence
An analysis of individuals with T2DM in the French national health insurance database found that the risk of medullary thyroid cancer (MTC) increased by 78% (95% CI: 1.4–3.05)... among those taking GLP-1RAs for 1–3 years [41].
Why this rating
Conflicting data between observational studies (increased risk) and RCTs/meta-analyses (no significant risk).
Source
Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity
Edward R. Sauter et al. · Cancers · 2024
DOI 10.3390/cancers16193275
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sustained weight loss of at least 5% achieved through pharmacotherapy or bariatric surgery is associated with a reduced risk of obesity-related cancers.Good
- GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) reduce cancer risk in overweight/obese individuals primarily through sustained weight loss and secondarily through weight-loss-independent anti-inflammatory and metabolic mechanisms.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →